United States · Medical and donor conditions

A consultation desk with a microscope visible in a laboratory through glass.
Editorial illustration only; it does not depict a real clinic or establish legal compliance.

US Surrogacy: Medical and Donor Requirements

Start with the right legal distinction

There is no single US-wide medical checklist for a gestational-carrier IVF arrangement. Separate the federal FDA rules for reproductive tissue and genetic contributors, the law of the relevant state, ASRM’s clinical recommendations, and the clinic’s own acceptance policy. FDA donor rules focus on communicable-disease screening and testing of reproductive cells and tissues; they do not treat the carrier as a tissue donor or require FDA donor testing of the carrier. ASRM nevertheless recommends carrier screening. A clinic may decline a case under its policy even where no federal rule categorically bars it.

Do not treat every requirement as the same kind of law. 21 CFR Part 1271 governs donor eligibility, screening, testing, handling, records and labels for covered human cells and tissues. State law may add requirements for fertility practices, donors or carrier arrangements. ASRM guidance is professional medical advice, not itself a federal statute, although clinics may adopt it as policy or a standard of care. Clinics may also apply stricter criteria. Ask whether each test or exclusion comes from legislation, regulation, ASRM guidance, laboratory protocol or the clinic’s own policy.

Screening the gestational carrier

ASRM recommends that a carrier be of legal age and preferably 21–45 years old. Ideally, she has had at least one full-term, uncomplicated pregnancy and no more than five previous deliveries or three caesarean deliveries, with a stable support environment. These are professional recommendations, not universal federal statutory limits. State law and clinic policy may be stricter. A history outside the preferred profile calls for an individual review of applicable law, obstetric risk and clinic criteria—not an unsupported claim that federal law automatically disqualifies the person.

Carrier assessment should go beyond age. ASRM describes medical and obstetric history, physical examination, laboratory and preconception testing, uterine-cavity assessment, psychosocial evaluation and counselling, and legal counselling. Review prior pregnancies and deliveries, caesarean history, complications, medicines, chronic conditions and any risk that could make pregnancy unsafe. The exact tests and thresholds depend on the clinical facts and applicable state and clinic rules. Ask which records are required and whether each finding is a contraindication, a manageable risk or a clinic-specific exclusion. ASRM’s preconception list also includes blood type/Rh, cervical-cancer screening and mammography under ACOG guidance, rubella and varicella immunity, urine drug screening and vaccination planning. Its practice opinion also calls for psychological evaluation and implications counselling by a qualified mental-health professional for the carrier and her partner or support person. These are professional recommendations, not a single federal statutory checklist.

ASRM recommends infection screening and testing of the carrier and her partner before embryo transfer, although FDA donor-eligibility rules do not require this testing for a person in the carrier role. Its 2022 guidance lists HIV-1, HIV-2 and HIV group O antibodies; hepatitis B surface antigen and core antibodies (IgG/IgM); HCV antibody; HIV, HBV and HCV nucleic-acid tests; syphilis serology; and nucleic-acid tests for gonorrhoea and chlamydia. HTLV-I/II and CMV IgG/IgM are listed for the carrier’s male partner. Confirm current assays, timing and repeat-test rules with the clinic; this is clinical guidance, not a universal federal test order.

A positive or abnormal result needs a documented clinical response, not an assumption. ASRM recommends confirmation and appropriate counselling. Its guidance generally advises against using a carrier with confirmed HIV or hepatitis B or C, while any exceptional case requires especially careful counselling, informed consent and documentation. For syphilis, gonorrhoea or chlamydia, ASRM calls for treatment, retesting and deferral until treatment succeeds and the person is no longer infectious. These are clinical recommendations, not one statute covering every test. Ask for the result, confirmation process, treatment plan and decision criteria.

Gamete sources and FDA rules

Under 21 CFR §§ 1271.45 and 1271.50, the responsible establishment generally must document donor eligibility based on screening and testing before covered reproductive cells or tissues are used, subject to specific exceptions. When an embryo is intended for a carrier, assess the oocyte and semen sources separately. ASRM’s current guidance says FDA donor-eligibility assessment applies to sperm and oocyte sources when a carrier is planned. The carrier is the embryo recipient for these purposes, not its donor. Ask the clinic or tissue establishment who makes and records each determination. Screening is more than lab testing: § 1271.75 requires review of medical records for specified risk factors and clinical signs of communicable disease. Request the screening/history record, any physical-exam information used, lab reports and written eligibility decision.

Federal donor testing primarily addresses communicable-disease risk; it cannot eliminate all infectious or genetic risk. FDA and ASRM materials identify testing for HIV-1/2, hepatitis B and C, syphilis, chlamydia and gonorrhoea. ASRM’s 2024 summary of FDA requirements also lists HTLV-I/II and cytomegalovirus testing for sperm sources, and lists WNV nucleic-acid amplification testing (NAT) among FDA-required tests for gamete donors. It notes that WNV testing may be year-round or seasonal for gametes recovered from June 1 through October 31. FDA’s current donor-testing webpage likewise states that living HCT/P donors must receive WNV NAT, subject to § 1271.90 exceptions. However, WNV is not expressly named in § 1271.85, and the September 2016 FDA WNV guidance expressly says it is nonbinding while describing seasonal testing at U.S. establishments from June 1 through October 31 and year-round testing by non-U.S. establishments intending to import HCT/Ps into the United States. Do not present those seasonal dates as text of the regulation or infer the complete legal position from § 1271.85 alone. Ask the tissue establishment’s compliance team to confirm the current FDA instructions, assay, timing and any applicable exception.

Timing can control release of material. Under 21 CFR § 1271.80, donor specimens are generally collected at recovery or within seven days before or after; for oocytes, collection may be up to 30 days before recovery or within seven days after. Anonymous semen requires six-month quarantine and repeat infectious-disease testing under §§ 1271.60 and 1271.85(d). Directed semen donors are exempt from that federal six-month retest, but testing still applies and the specimen is generally collected within seven days of acquisition. ASRM recommends a more cautious quarantine of more than 35 days and repeat testing for directed samples. FDA does not require oocyte quarantine. Check dates for every sample and batch.

A known or directed donor is not an untested donor. Directed sperm and oocyte donors still undergo applicable screening and infectious-disease testing. Federal rules allow certain reproductive tissue from a directed donor found ineligible because of required screening/testing to be used only under a narrow exception, with prescribed warnings and records. This narrow exception does not erase the result, remove the need to address risk or force a clinic to accept the material. ASRM recommends disclosure and appropriate recipient counselling, with donor consent, before use. A clinic or state may impose stricter limits. § 1271.65(b) requires the Biohazard legend and “WARNING: Advise patient of communicable disease risks”. Reactive results also require “WARNING: Reactive test results for (name of disease agent or disease).” Verify § 1271.55 records and documented notice to the physician using the tissue.

The sexually intimate partner exception is not automatic for intended parents. Under 21 CFR § 1271.90(a)(2), the donor must be the recipient’s sexually intimate partner. In a gestational-carrier arrangement, an intended parent supplying sperm or oocytes is not ordinarily the carrier’s intimate partner, so do not presume that exception applies. A separate provision, § 1271.90(a)(4), covers certain cryopreserved embryos that were originally excepted under the intimate-partner rule when recovered or cryopreserved and are later intended for directed or anonymous donation. When possible, appropriate measures should be taken to screen and test the sperm and oocyte sources before transfer; check the specific labeling requirements in § 1271.90(c), including paragraph (c)(6) where applicable. Section 1271.90(b) separately permits certain embryos originally intended for a specific individual or couple to be donated for reproductive use even when donor-eligibility requirements are not met. However, it does not excuse a failure to make the required eligibility determination for either gamete source or deficiencies in donor screening or testing under §§ 1271.75, 1271.80 and 1271.85. A change in recipient or purpose can change the analysis. Before transfer, ask the laboratory to document the embryo’s original purpose, donor relationships, the exact exception relied on, completion of required screening/testing and eligibility determinations, and any required labels.

Genetics and recipient assessment

Infectious-disease eligibility is separate from genetic screening. ASRM recommends medical and family histories and appropriate genetic evaluation of genetic contributors. It identifies carrier screening for cystic fibrosis, spinal muscular atrophy and thalassaemias or other haemoglobinopathies; expanded screening may be appropriate. Ideally, sperm and oocyte sources are screened for the same conditions so combined reproductive risk can be assessed. Genetic counselling may be needed for overlapping findings or a significant family history. These recommendations go beyond FDA infectious-disease eligibility and are not one universal federal genetic panel. Ask for the panel, residual-risk explanation and plan for shared carrier findings.

Recipients and intended parents need a separate plan. ASRM recommends relevant medical and infectious-disease evaluation of recipients and, where appropriate, their intimate partners, although FDA generally does not require recipient testing as part of donor eligibility. Preconception review may include blood group and Rh status, antibody screening, vaccination status, relevant infections and conditions affecting pregnancy care. If an intended parent provides gametes for a carrier pregnancy, distinguish that person’s status as a genetic contributor under FDA tissue rules from the separate clinical assessment of the parent or recipient. Ask which tests are mandatory, recommended or clinic-specific.

Records and decision matrix

Request a written checklist and keep the records together. Depending on the role and applicable rules, records may include carrier obstetric history and questionnaire; examination and laboratory results with collection dates; medical and psychosocial evaluations; genetic and family histories; donor screening and eligibility determinations; consent and risk-counselling records; the clinic’s written protocol; and required tissue labels and accompanying records. Not every item is a universal statutory document for every participant, so the checklist should state its legal or clinical basis. For each sample, record whether donation is directed, which recipient is relevant, whether quarantine or retesting applies, and who authorised release. Federal rules require records pertaining to a covered HCT/P to be kept for at least 10 years after its administration; if the administration date is unknown, keep them for at least 10 years after distribution, disposition, or expiration, whichever is latest (21 CFR § 1271.55(d)(4)). ASRM recommends permanent retention of each donor’s screening and test results. For a carrier arrangement, ASRM also recommends independent legal counsel for each party licensed in the applicable state and, before treatment, a fully executed agreement, legal-clearance letter and informed-consent documents, including an appropriate medical-information release. State law and the exact arrangement still need review. For ineligible directed material, retain required labels/records and proof of physician notification.

Decision pointLegal or clinical meaning and next step
Gestational carrierFederal FDA donor rules treat the carrier as recipient, not reproductive-tissue donor. ASRM recommends medical, infectious, obstetric and psychosocial screening and counselling; a prior uncomplicated term pregnancy is preferred. State law, actual health history and clinic criteria may change the outcome. Ask for the state-specific rule and written clinic protocol; do not present ASRM’s preferred age or pregnancy history as federal law.
Sperm or oocyte sourceFederal rules generally require donor screening, specified infectious testing and a documented eligibility determination, subject to exceptions. Timing differs by tissue type; anonymous semen has six-month quarantine and retesting, while directed semen follows a different federal pathway. ASRM may recommend extra safeguards. Before use, obtain the laboratory panel, collection dates, directed/nondirected status, quarantine status, eligibility record and any required labels. For ineligible directed tissue, verify warnings, records and documented physician notice.
Genetic contributors and recipientsFDA donor rules focus on communicable-disease risks for genetic contributors, subject to specific exceptions. ASRM recommends genetic carrier screening, family-history review, recipient evaluation and counselling beyond the federal infectious-disease minimum. Compare results from both genetic sources, explain residual risk and document shared carrier findings. A negative infection panel does not establish that genetic risk is absent, and an ASRM recommendation is not automatically a statute.
State and clinicState law may add requirements and can differ by location; professional guidance does not replace it. Clinic policy may be stricter than the legal minimum and determine whether a candidate or donor is accepted. Identify the state where treatment and relevant medical services occur, ask the clinic to cite each mandatory exclusion, and confirm the tissue establishment’s required registration and records. FDA acceptance of establishment registration and HCT/P listing does not determine that the establishment complies with applicable rules or that the HCT/P is licensed or approved by FDA.

Warning signs and next steps

Pause before paying or arranging transfer if the clinic cannot identify the rule behind an exclusion; donor tests or dates are missing; a known donor is said to be exempt from all testing; ineligible material is proposed without risk counselling, required warnings, records or documented physician notice; the intimate-partner exception is assumed to cover the carrier; or an ASRM preference is described as federal law. These facts do not by themselves prove misconduct, but justify requesting the actual regulation, written protocol, laboratory records and state-specific legal review before relying on the plan.

Use this sequence: (1) identify the state, treatment pathway, gamete sources and carrier; (2) obtain written carrier, donor and recipient protocols; (3) classify each requirement as law, FDA rule, ASRM recommendation or clinic policy; (4) collect relevant histories and laboratory reports; (5) verify dates, quarantine, retesting, labels and eligibility determinations for every sample; (6) resolve abnormal results through clinicians and documented counselling; and (7) ask a lawyer familiar with the state to review local restrictions and the arrangement’s legal effect. Recheck rules at treatment. This guide does not determine that a particular person or clinic is eligible.

Primary sources and professional guidance

Last updated:

Author: Khachatrian Razmik, LL.M.

International surrogacy and parentage legal services — LEX SURROGACY by Lex Agency · Author profile · Editorial standards